Progesterone (Progestin) Veterinary Grade API is a white to creamy-white crystalline powder supplied under the grade code P4-VET-M25, where the suffix identifies a micronized lot with a D90 not exceeding 25 µm by laser diffraction. The material is manufactured under EU GMP Part II and is tested against Ph. Eur. 0418 for identity, assay, related substances, loss on drying, and sulfated ash. Residual solvent control follows VICH GL18, elemental impurity control follows VICH GL19, and stability data are generated according to VICH GL3R. The API is intended for formulation into tablets, oily injections, capsules, powders, granules, premixes, and solutions for reproductive management in cattle, equine, porcine, canine, and feline species, subject to national registration and prescribing restrictions. The product is a starting material for licensed dosage-form manufacture; it is not a finished veterinary medicine for direct administration.

In solid oral dosage forms, the micronized fraction controls dissolution and content uniformity. Progesterone aqueous solubility is approximately 5–10 µg/mL at 25 °C; therefore, tablet and capsule formulations require particle size reduction, surfactant wetting, or lipid-based vehicles to achieve reproducible release. Without controlled particle size, content uniformity values under USP <905> can exceed an acceptance value of 15, particularly in low-dose tablets containing 1–5% active pharmaceutical ingredient. Formulators should also distinguish between veterinary-grade API and finished veterinary medicines: in the European Union, finished products are authorized under Regulation (EU) 2019/6; in the United States, new animal drug approval or legal extra-label use under 21 CFR 530 may apply.

What Analytical Limits Govern Release for Veterinary Progesterone API?

The compendial release profile is set to control identity, purity, residual manufacturing solvents, and particle size. The following limits are representative of a micronized veterinary progesterone API aligned to the current pharmacopeial monograph.

Identity is confirmed by infrared absorption spectrophotometry against a current reference standard and by retention time in the related-substances liquid chromatographic assay. The Ph. Eur. 2.2.29 method uses reversed-phase liquid chromatography with UV detection at 241 nm; related 20-beta-hydroxyprogesterone and other process impurities are resolved. For injectable applications, the API is not supplied as a sterile grade; terminal sterilization or aseptic processing of the finished dosage form is required. Bioburden and endotoxin limits are established at the finished-product stage under 21 CFR 211 and USP <85> where applicable.

Micronization increases specific surface area but also increases static charge and reduces bulk density. A micronized progesterone lot can exhibit a bulk density of 0.25–0.40 g/cm³ and a tap density of 0.45–0.65 g/cm³, yielding a Hausner ratio between 1.3 and 1.7. These values indicate cohesive flow, which is managed by wet granulation or by blending with fumed silica at 0.5–1.0%. Polymorph control is verified by differential scanning calorimetry; the compendial polymorph melts at 126–131 °C, and a shift below 124 °C can indicate amorphous content or a different polymorph. Formulation processes that generate sustained temperatures above 40 °C do not convert the stable polymorph, but grinding can introduce lattice disorder. In direct compression, compaction pressure exceeding 12–15 kN can cause capping due to the elastic recovery of the crystalline material. Storage at relative humidity above 60% can increase water uptake and reduce flow; desiccant-lined packaging or controlled humidity below 40% RH is used in tropical supply chains.

Oil-Based Injection Formulations, Syringeability Thresholds, and Cold-Storage Precipitation

Injectable progesterone veterinary products are typically prepared as oily solutions or suspensions at 25–50 mg/mL using ethyl oleate, sesame oil, or medium-chain triglycerides. Vehicle viscosity at 20 °C ranges from 8–15 mPa·s for ethyl oleate to 30–60 mPa·s for sesame oil; syringeability in 21 G needles becomes unreliable when viscosity exceeds 60 mPa·s. Cold storage below 15 °C can cause progesterone to precipitate in oil solutions; warming to 30–35 °C for several minutes restores clarity in most formulations, but repeated thermal cycling can promote particle growth. In suspensions, particle size stability is a critical quality attribute; an increase in D90 above 25 µm over the shelf life may increase risk of needle obstruction and injection-site granulomas. Terminal sterilization of progesterone oil formulations at 121 °C for 15 min is feasible where stability data support it, but saturated oily solutions may require antioxidant protection with alpha-tocopherol 0.01–0.05%.

In tablet manufacture, two challenges dominate: poor compactibility of the crystalline API and high sensitivity to magnesium stearate. A direct compression batch using 10–20% micronized progesterone, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium 2–4%, and magnesium stearate 0.5–1.0% can meet USP <1216> friability below 1.0% if compression force is kept below 12 kN. Dissolution testing per USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid with 0.5% sodium lauryl sulfate is used to compare batches; without surfactant, dissolution is too low to discriminate. Capsule filling of micronized progesterone requires granulation or adequate flow aids because static charge can cause weight variation above ±5% relative standard deviation on automatic tamping machines. Granulation with povidone K30 at 5–10% binder solution in a fluid-bed granulator with inlet air temperature 55–65 °C and final moisture 2–4% reduces segregation and improves die filling. Dry granulation via slugging or roller compaction can be used when wet granulation is undesirable; roll compaction at 40–70 kN and milling through a 0.8–1.2 mm screen produces granules with acceptable flow and lower water exposure. Such granules may still require extragranular disintegrant to preserve tablet disintegration below 15 min.

When Low-Dose Premix Blending Requires Delumping and Surfactant Wetting

In veterinary premixes, progesterone is incorporated at 0.1%–2.0% active concentration into carriers such as lactose monohydrate, calcium carbonate, corn cob meal, or silicon dioxide. At 0.1% loading, simple ribbon blending often produces a coefficient of variation above 5% unless staged geometric dilution is used. A ribbon blender operated at 15–20 rpm for 20–30 min is often insufficient to break electrostatic agglomerates; a high-shear mixer with a chopper speed of 2500–3000 rpm for 3–5 min may be required before final blending. Carrier moisture above 8% can promote cohesion and caking. A premix batch is considered homogeneous when 10 sampled locations have assay values within 90.0%–110.0% of label claim and a relative standard deviation below 5.0%. Sieve analysis after blending typically targets 95% passing 500 µm and not more than 20% below 150 µm to minimize dusting. Published data for species-specific oral bioavailability from progesterone premix formulations in cattle remain limited; formulation comparisons therefore rely on in vitro content uniformity, particle-size retention, and dissolution rather than plasma AUC extrapolation.

Batch-to-batch variance is controlled by requiring the supplier to maintain particle-size distribution within a D10 not less than 1 µm, D50 between 5 µm and 15 µm, and D90 below 25 µm. A change from one micronization vendor to another may alter the angle of repose from 35° to 50° and shift tablet disintegration times by more than 2 min. Only comparative dissolution and content uniformity data can justify such a change. Prolonged contact with strong mineral acids or alkalis should be avoided in formulation development because hydrolytic degradation can occur under stress conditions, even though the API is stable under normal solid-state storage.

Synthetic progestins differ in receptor occupancy, clearance, and species-approved indications.

The following comparative profile distinguishes progesterone from synthetic progestins encountered in veterinary practice.

Progesterone and synthetic progestins cannot be substituted at equal milligram doses because receptor-binding affinity, hepatic extraction, and species-specific regulatory status differ. Formulators using this veterinary-grade progesterone should treat the API as a bioidentical steroid with narrow aqueous solubility and pronounced processing sensitivity rather than as a robust direct-compression ingredient. Published comparative bioavailability data for all veterinary species are incomplete; when such data are absent, formulation development relies on pharmacopeial dissolution, content uniformity, and particle-size release criteria rather than clinical AUC extrapolation.

For aqueous-based solutions, solubility is achieved by co-solvents or inclusion complexes rather than by salt formation because progesterone has no ionizable group. A 1.0 mg/mL solution may require 10–20% ethanol or propylene glycol, or hydroxypropyl-beta-cyclodextrin at a 1:1 to 1:2 molar ratio. Viscosity of the final oral solution at 20 °C is kept below 20 mPa·s for accurate drop or syringe delivery. Aqueous vehicles require antimicrobial preservation, commonly benzyl alcohol at 1.5–2.0% or parabens; ethanol-containing solutions without water may not require the same preservation but need child-resistant closure systems for veterinary use. pH adjustment does not materially affect progesterone solubility, so dissolution is controlled by wetting and micellar solubilization rather than ionization. Solutions for injection require terminal sterilization or aseptic filtration after confirming filter compatibility; adsorptive losses on sterilizing-grade membranes should be evaluated because progesterone can bind to hydrophobic filter materials.